Navigation Links
Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
Date:4/22/2008

AMSTERDAM, Netherlands and SANTA CLARA, Calif., April 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, and Agilent Technologies, Inc. (NYSE: A), today announced terms under which they intend to collaborate to develop new in-vitro diagnostic tests. In addition, the two companies announced an agreement in which Agendia products will continue to be supplied on Agilent microarrays through December 31, 2011. Agilent has been manufacturing the components for the Agendia assay since its inception in 2003. The financial terms of the agreement were not disclosed.

"We've established and enjoyed a strong business relationship with Agilent since the incorporation of Agendia," said Dr. Bernhard Sixt, CEO and co- founder of Agendia. "These activities, including joint research and development, have allowed our two companies to forge an even closer strategic alliance focused on Agendia's core competencies, namely the discovery of biomarkers and development of new diagnostic tests for clinical use, which are regulated under the new IVDMIA guidelines of the FDA."

"We're proud that Agendia has selected Agilent to move forward with their critical work in diagnosing breast cancer," said Yvonne Linney, Ph.D., vice president and general manager, Genomics at Agilent. "We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels."

Last year, Agendia's MammaPrint(R), a molecular diagnostic tool developed to help physicians make informed decisions in treating breast cancer, became the first IVDMIA microarray-based diagnostic test cleared by the United States Food and Drug Administration (FDA). The tests, which are manufactured on Agilent microarrays, are performed at Agendia's laboratory in The Netherlands. Agendia also offers DiscoverPrint, a gene expression-based service for improving the efficacy of clinical trials, and CupPrint, a diagnostic test designed to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary." These are also manufactured using Agilent microarrays.

Both companies will share information about their research into genetic biomarkers and jointly assess the commercial potential of each opportunity.

About Agilent Technologies

Agilent is a leading provider of research microarrays used to analyze gene expression, microRNA, comparative genomic hybridization and ChIP-on-chip. More information about Agilent microarrays is available at http://www.opengenomics.com. Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.4 billion in fiscal year 2007. Information about Agilent is available on the Web at http://www.agilent.com.

About Agendia

Agendia BV, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics. With three products on the market and an expanding market base, the company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA clearance for its breast cancer test, MammaPrint(R), which predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test designed to identify the origin of the primary tumor in "Cancer of Unknown Primary." Agendia also recently presented data to be developed into its new clinical colon cancer prognosis test, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with leading academic centers around the world to develop state of the art diagnostic tests for cancer. The company also offers its expertise and its DiscoverPrint(R) service to pharmaceutical and biotech companies focusing on development of highly effective precision therapeutics in oncology. For more information on Agendia, visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx

MEDIA CONTACTS:

For Agendia - EU & non-U.S.-based Media: For Agilent:

Bernhard Sixt Stuart Matlow

CEO Agilent

Agendia +1.408.553.7191

+31 20 512 9161 stuart_matlow@agilent.com

info@agendia.com

For Agendia - U.S. Media:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

Kelly.connor@ogilvypr.com


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Appoints Clinical and Scientific Advisory Board
2. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia Joins the Personalized Medicine Coalition (PMC)
5. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
6. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
7. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
8. Fufeng Announces 2007 Annual Results
9. Pharmacyclics Announces It Received Nasdaq Notification
10. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
Breaking Biology News(10 mins):